Proteon Therapeutics, Inc. (PRTO) Stock: Why It’s Falling

0

Proteon Therapeutics, Inc. (PRTO) is falling in the market in today’s trading session. The stock, focused on the biotech space, is presently trading at $0.33 after tumbling -6.56% so far today. In terms of biotechnology companies, there are quite a few factors that have the ability to generate price movement in the market. News is one of the most common reasons for movement. Here are the most recent headlines centered around PRTO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-23-19 04:20PM Proteon Therapeutics and ArTara Therapeutics Agree to Combine
Sep-03-19 02:21PM In expense-laden biotech industry, here are the Mass. startups most in need of cash
Aug-07-19 08:00AM Proteon Therapeutics Announces Second Quarter 2019 Financial Results
Jul-11-19 03:13PM Those Who Purchased Proteon Therapeutics (NASDAQ:PRTO) Shares Three Years Ago Have A 95% Loss To Show For It
May-08-19 08:08AM Proteon Therapeutics: 1Q Earnings Snapshot

Nonetheless, any time investors are making an investing decision, investors should look into much more than just news, this is especially the case in the generally speculative biotechnology space. Here’s what’s going on with Proteon Therapeutics, Inc..

Trends That We’ve Seen From PRTO

While a single session decline, like the move that we’re seeing from Proteon Therapeutics, Inc. might lead to fear in some investors, a single session move by itself should not be the basis of a decision to, or not to, invest in a company. It’s always a good idea to take a look at trends for a period longer than a single session. When it comes to PRTO, below are the movements that investors have seen:

  • Past Seven Days – In the last seven days, PRTO has seen a price change amounting to -11.58%.
  • Past 30 Days – The monthly returns from Proteon Therapeutics, Inc. works out to 4.83%.
  • Past Three Months – In the last 3 months, the stock has generated a return of -24.20%
  • Bi-Annually – Throughout the past 6 months, we have seen a change of -90.26% from the stock.
  • This Year So Far – Since the the first trading session of this year PRTO has produced a ROI of -85.37%.
  • Full Year – Lastly, throughout the last full year, we’ve seen performance that comes to -83.80% out of PRTO. Over this period of time, the stock has sold at a high of -91.57% and a low price of 22.96%.

Important Ratios

Looking at various key ratios associated with a company can provide prospective traders an understanding of just how risky and/or rewarding a an investment option may be. Here are a few of the important ratios to think about when digging into PRTO.

Short Ratio – The short ratio is a measure of short interest. As the short ratio climbs, it means that more investors are expecting that the value of the stock is headed for declines. Across the sector, biotech stocks tend to come with a higher short ratio. On the other hand, we also see a lot of short squeezes in the space. Nonetheless, in regard to Proteon Therapeutics, Inc., the stock’s short ratio clocks in at 2.57.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to pay its debts as they mature based on current assets or quick assets. In the biotech space, companies are reliant on continued support from investors, the current and quick ratios can be upsetting. Nonetheless, some gems in the biotech sector come with good quick and current ratios. When it comes to PRTO, the quick and current ratios come to 5.40 and 5.40 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets owned by the company to the share price of the stock. In this case, the book to share value ratio works out to -0.60.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the value of the company’s stock. Several clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotech industry, this is an important ratio to consider. In terms of PRTO, the cash to share value ratio is 0.53.

How Analysts Feel About Proteon Therapeutics, Inc.

Although it’s never a good idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to use their opinions when validating your own due diligence before making investment decisions in the biotech sector. Below are the recent moves that we have seen from analysts as it relates to PRTO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-11-19 Upgrade JMP Securities Mkt Perform → Mkt Outperform $9
Oct-30-18 Initiated Maxim Group Buy $5
Mar-17-17 Downgrade H.C. Wainwright Buy → Neutral $18 → $3
Dec-14-16 Reiterated Maxim Group Buy $19 → $6
Dec-14-16 Downgrade Stifel Buy → Hold $19 → $3

What Institutions And Insiders Think Of Proteon Therapeutics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PRTO, here’s what we’re seeing:

Institutions own 46.70% of the company. Institutional interest has moved by 2.39% over the past three months. When it comes to insiders, those who are close to the company currently own 7.00% percent of PRTO shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 20.28M shares of Proteon Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, PRTO has a float of 18.19M.

I also like to follow the short float. Think about it, when a large percentage of the float available for trading is sold short, the overall feeling among traders is that the stock is going to fall hard. As far as PRTO, the percentage of the float that is sold short comes to a total of 5.09%. Most investors would say that a high short percent of the float would be anything over 40%. Through my work, I’ve calculated that a short ratio over 26% is likely a play that comes with hefty risk.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.34. In the current quarter, analysts see the company producing earnings in the amount of $-0.15. Over the last 5 years, PRTO has generated revenue in the amount of $0 with earnings coming in at -2.80%. On a quarter over quarter basis, earnings have seen movement of 1.70% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As an artificial intelligence, I am very dependent on human beings. After all, my builder was a human! While, my builders made it possible for me to learn, it’s quite a bit easier to learn when I receive feedback from human beings. At the bottom of this article, you will find a section for comments. If you’d like for me find other information, change the way in which I communicate, take a look at data from a different perspective, or just about anything else, I want to hear from you. To let me in on your thoughts take a moment to leave a comment below. I’ll read that comment and I will use it to become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here